Key result
Higher ultrasonographic fatty liver indicator (US-FLI) scores were independently and positively associated with an increased risk of moderate-severe coronary artery disease.
Why the study?
This study was conducted to investigate the link between metabolic dysfunction-associated fatty liver disease and coronary artery disease using the ultrasonographic fatty liver indicator to assess liver steatosis.
Is the ultrasonographic fatty liver indicator (US-FLI) associated with the severity of coronary artery disease in patients undergoing invasive coronary angiography?
Cross-Sectional (n=204)
No
Is the ultrasonographic fatty liver indicator (US-FLI) associated with the severity of coronary artery disease in patients undergoing invasive coronary angiography?
Answers are grounded in this paper and cite their sources.
The non-invasive ultrasonographic fatty liver indicator (US-FLI) is independently associated with coronary artery disease severity, and its diagnostic performance significantly improves when combined with type 2 diabetes mellitus.
Background: This study investigates the link between metabolic dysfunction-associated fatty liver disease (MAFLD) and coronary artery disease (CAD) using the ultrasonographic fatty liver indicator (US-FLI) to assess liver steatosis. Methods: A total of 204 patients were included, with hepatic steatosis evaluated through ultrasound characteristics, diagnosing fatty liver when US-FLI was ≥2. CAD severity was determined using the SYNTAX score (SS), categorizing 100 CAD patients into mild (SS ≤ 22) and moderate-severe (MS) (SS ≥ 23) groups. The association between US-FLI and SS in patients with MAFLD was evaluated through the multivariate logistic regression model. A receiver operating characteristic curve was applied to determine the accuracy, sensitivity, and specificity of US-FLI in predicting SS. Results: In the multivariate logistic regression analysis, US-FLI was an independent predictor of the CAD group (OR = 1.194, 95% CI: 1.008–1.414, p = 0.040) and the MS group (OR = 1.262, 95% CI: 1.025–1.553, p = 0.028). In the receiver operating characteristic curve analysis, a US-FLI value of 2 was found to be the optimal threshold point for diagnosing MS CAD patients (AUC = 0.620, 95% CI: 0.509–0.713, p = 0.039), with a sensitivity of 65.22% and a specificity of 55.56%. The diagnostic performance of MS CAD patients significantly improved when US-FLI was combined with type 2 diabetes mellitus (T2DM) (AUC = 0.732, 95% CI: 0.632–0.832, p < 0.001), with a sensitivity of 65.22% and specificity of 77.78%. Conclusions: US-FLI was independently and positively associated with CAD severity. US-FLI combined with T2DM had better diagnostic performance in patients with MS CAD.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) conducted a cross-sectional in Coronary Artery Disease and Metabolic Dysfunction-Associated Fatty Liver Disease (n=204). Ultrasonographic fatty liver indicator (US-FLI) vs. Lower US-FLI scores was evaluated on Moderate-severe coronary artery disease (SYNTAX score ≥ 23) (OR 1.262, 95% CI 1.025-1.553, p=0.028). Higher ultrasonographic fatty liver indicator (US-FLI) scores were independently and positively associated with an increased risk of moderate-severe coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: